Literature DB >> 15994930

Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease.

Harriet M Kluger1, Dina Chelouche Lev, Yuval Kluger, Mary M McCarthy, Galina Kiriakova, Robert L Camp, David L Rimm, Janet E Price.   

Abstract

Metastasis is the primary cause of death from breast cancer. A xenograft model was used to identify genes potentially involved with metastasis, comparing expression in the poorly metastatic GI101A human breast cancer cell line and a highly metastatic variant, GILM2. cDNA microarray analyses of these isogenic variants were done using 16K Operon 70-mer oligonucleotide microarray slides. Differentially expressed genes were identified by ANOVA, and differences of > or =2.5-fold were found for 106 genes. Changes in protein or RNA expression were confirmed for 10 of 12 genes. Three markers, heat shock protein 70 (HSP-70), chemokine (C-X-C motif) ligand 1 (CXCL-1), and secreted leukocyte protease inhibitor (SLPI), were studied further with breast cancer tissue microarrays using a novel method of automated quantitative analysis. This uses cytokeratin to define pixels as breast cancer (tumor mask) within the tissue array spot and then measures intensity of marker expression using a cyanine 5-conjugated antibody within the mask. Scores were correlated with clinicopathologic variables. High HSP-70 expression and high nuclear CXCL-1 expression in primary tumors were both associated with decreased survival (P = 0.05 and 0.027, respectively). Expression of each marker was strongly associated with lymph node involvement (P = 0.0002, 0.008, 0.0012, and 0.012 for HSP-70, nuclear CXCL-1, cytoplasmic CXCL-1, and SLPI, respectively). Identification of genes associated with metastasis in experimental models may have clinical implications for the management of breast cancer, because some of these are associated with lymph node metastasis and survival and might be useful as prognostic markers or molecular targets for novel therapies.

Entities:  

Mesh:

Year:  2005        PMID: 15994930     DOI: 10.1158/0008-5472.CAN-05-0108

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Proteomic research progress in lymphatic metastases of cancers.

Authors:  Junwei Zong; Chunmei Guo; Shuqing Liu; Ming-Zhong Sun; Jianwu Tang
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

2.  PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Authors:  Lucia B Jilaveanu; Fabio Parisi; Meaghan L Barr; Christopher R Zito; William Cruz-Munoz; Robert S Kerbel; David L Rimm; Marcus W Bosenberg; Ruth Halaban; Yuval Kluger; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

3.  Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.

Authors:  Eleftheria Kalogera; Nathalie Scholler; Cecelia Powless; Amy Weaver; Ronny Drapkin; Jinping Li; Shi-Wen Jiang; Karl Podratz; Nicole Urban; Sean C Dowdy
Journal:  Gynecol Oncol       Date:  2011-10-28       Impact factor: 5.482

4.  Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis.

Authors:  Xin Zhang; Ling Su; Ali A Pirani; Haiyan Wu; Hongzheng Zhang; Dong M Shin; Kim M Gernert; Zhuo Georgia Chen
Journal:  Clin Exp Metastasis       Date:  2006-09-22       Impact factor: 5.150

5.  Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.

Authors:  D Zheng; B Gui; K P Gray; I Tinay; S Rafiei; Q Huang; C J Sweeney; A S Kibel; L Jia
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

6.  Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Authors:  Joao Incio; Jennifer A Ligibel; Daniel T McManus; Priya Suboj; Keehoon Jung; Kosuke Kawaguchi; Matthias Pinter; Suboj Babykutty; Shan M Chin; Trupti D Vardam; Yuhui Huang; Nuh N Rahbari; Sylvie Roberge; Dannie Wang; Igor L Gomes-Santos; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Sara M Tolaney; Ian E Krop; Dan G Duda; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2018-03-14       Impact factor: 17.956

7.  The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway.

Authors:  T Sugino; T Yamaguchi; G Ogura; T Kusakabe; S Goodison; Y Homma; T Suzuki
Journal:  J Pathol       Date:  2007-06       Impact factor: 7.996

8.  Genomic signatures of breast cancer metastasis.

Authors:  V Urquidi; S Goodison
Journal:  Cytogenet Genome Res       Date:  2007       Impact factor: 1.636

Review 9.  Cancer proteomics by quantitative shotgun proteomics.

Authors:  Emily I Chen; John R Yates
Journal:  Mol Oncol       Date:  2007-09       Impact factor: 6.603

10.  Role of cancer microenvironment in metastasis: focus on colon cancer.

Authors:  Stéphanie Gout; Jacques Huot
Journal:  Cancer Microenviron       Date:  2008-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.